Orexo’s annual report for 2014 released

Orexo’s annual report for the 2014 fiscal year has been published and can be
downloaded from the investor section of the company’s homepage
www.orexo.com/ar/2014/en/.

For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46-18 780 88 50, E-mail: ir@orexo.com


About Orexo
Orexo is an integrated pharmaceutical company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery. The company is commercializing its proprietary product, Zubsolv®
sublingual tablets, for maintenance treatment of opioid dependence, in the
United States. The Zubsolv sublingual tablet is a novel formulation of
buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual
technologies. Orexo has a portfolio of two approved and revenue generating
products currently marketed under license in the US, EU and Japan. Orexo AB,
with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange (STO:
ORX) and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace
in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and
HealthCap.
For information about Orexo, please visit www.orexo.com


Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 9:30am CET on March 25, 2015.